Today, Senator Creigh Deeds stopped by AMPEL BioSolutions to visit with our employees and learn about how we are using Big Data to find and test new drugs for lupus patients. He got to see first-hand how our research is helping patients and their families have hope. We are very impressed with the questions Senator Deeds asked and his commitment to strengthening our biotechnology community here in Charlottesville.
On October 26 and 27, 2016 AMPEL participated in the Fall Job and Internship Fair hosted by the University of Virginia. To read more about this event visit: https://www.news.virginia.edu/content/potential-employers-descend-grounds-during-annual-career-fair
Grammer, far right, with her team from AMPEL BioSolutions, including from left to right, UVA alumnus Adam Labonte, Nick Geraci, Prathyusha Bachali, alumna Sarah Heuer and Rebecca Bender.
New results published in the professional journal Lupus demonstrate the effectiveness of an innovative system developed to identify promising treatments for lupus among existing drugs approved for use in other diseases. Funded by the Lupus Research Alliance and the John and Marcia Goldman Foundation, the study used Big Data to confirm selection of potential treatments identified by analyzing data on over 1,000 drugs approved by the U.S. Food and Drug Administration and eliciting broad feedback via internet crowd-sourcing.
The LRxL-STAT (Lupus Treatment List-SLE Treatment Acceleration Trials) was initiated by the Lupus Research Alliance) with Drs. Peter Lipsky and Amrie Grammer of AMPEL BioSolutions to address the urgent need for safer, more effective lupus treatments.
Click here to read the full article.
Crowd-sourcing, Literature Review and Big Data Analysis Identify Promising Lupus Treatments
NEW YORK, NY –- New results published in the professional journal Lupus demonstrate the effectiveness of an innovative system developed to identify promising treatments for lupus among existing drugs approved for use in other diseases. Funded by the Lupus Research Alliance and the John and Marcia Goldman Foundation, the study used Big Data to confirm selection of potential treatments identified by analyzing data on over 1,000 drugs approved by the U.S. Food and Drug Administration and eliciting broad feedback via internet crowd-sourcing.
Read entire article here
Drug Repositioning in SLE: Crowd-sourcing, Literature-mining, and Big Data Analysis
AC Grammer, MM Ryals, SE Heuer, RD Robl, S Madamanchi, LS Davis, B Lauwerys, MD Catalina, and PE Lipsky
Lupus patients are in need of modern drugs to treat specific manifestations of their disease effectively and safely. In the past half century, only one new treatment has been approved by the US Food and Drug Administration (FDA) for systemic lupus erythematosus (SLE). In 2014–2015, the FDA approved 71 new drugs, only one of which targeted a rheumatic disease and none of which was approved for use in SLE. Repositioning/repurposing drugs approved for other diseases using multiple approaches is one possible means to find new treatment options for lupus patients. ‘‘Big Data’’ analysis approaches this challenge from an unbiased standpoint whereas literature mining and crowd sourcing for candidates assessed by the CoLTs (Combined Lupus Treatment Scoring) system provide a hypothesis-based approach to rank potential therapeutic candidates for possible clinical application. Both approaches mitigate risk since the candidates assessed have largely been extensively tested in clinical trials for other indications. The usefulness of a multi-pronged approach to drug repositioning in lupus is highlighted by orthogonal confirmation of hypothesis-based drug repositioning predictions by ‘‘Big Data’’ analysis of differentially expressed genes from lupus patient samples. The goal is to identify novel therapies that have the potential to affect disease processes specifically. Involvement of SLE patients and the scientists that study this disease in thinking about new drugs that may be effective in lupus though crowd-sourcing sites such as LRxL-STAT (www.linkedin.com/in/lrxlstat) is important in stimulating the momentum needed to test these novel drug targets for efficacy in lupus rapidly in small, proof-of-concept trials conducted by LuCIN, the Lupus Clinical Investigators Network (www.linkedin.com/in/lucinstat). Lupus (2016) 25, 1150–1170
To read the complete article “Drug Repositioning in SLE: crowd-sourcing, literature-mining, and Big Data analysis” please click here.